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Abstract
In MS, a chronic demyelinating autoimmune disease, myelin is destroyed and is 
unable to be repaired. Current treatments focus on symptom alleviation and can 
cause many undesirable side effects. Mesenchymal stem cells (MSCs) are 
currently being investigated for their remyelination properties in MS. The studies 
selected for this research all aimed to assess safety as their primary objective. 
Though some minor adverse events were experienced, the MSC treatment did 
not lead to any major life-threatening events. The majority of the studies 
demonstrated significantly improved lesion volume on MRI and EDSS scores. 
Participants reported feeling better than they had prior to the study. Some 
studies have suggested using MSCs in conjunction with the currently approved 
medication as an option for treatment. It’s important to continue to study this 
topic and pursue the best possible treatment and care options for those suffering 
from MS.
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Neurons in the body are responsible for generating and conducting the electrical 
impulses which control our body’s functions and information processing. 
Neuronal axons are surrounded by a myelin sheath, which is vital for proper 
conduction of the impulses throughout the body. In MS, a chronic demyelinating 
autoimmune disease, the myelin is destroyed and is unable to be repaired. 
Current treatments for MS only focus on symptom alleviation and can cause 
many undesirable side effects. Mesenchymal stem cells (MSCs) are becoming 
more widely used in various treatments today thanks to their many unique 
properties. Recently, researchers have been directing their attention toward the 
use of MSCs in remyelination therapy for chronic MS patients.
Introduction
Methods
Several searches on PubMed and Ovid were conducted to find articles relevant 
to the topic. The initial search included human clinical trials from the last five 
years and each article was then evaluated and excluded via the following criteria 
• Studies including systematic reviews or meta-analysis. 
• Any articles featuring other inflammatory or autoimmune diseases besides 
MS. 
• Any studies involving treatment forms other than MSCs. 7 studies met this 
exclusion criteria and were utilized in the study.
While the studies failed to show significant outcomes and improvements in all 
the analyzed data, some significant results were seen and prove very 
promising. Many participants reported feeling better than they had prior to the 
study while being treated with MSCs. Some studies have suggested using MSCs 
in conjunction with the currently approved medication as an option for 
treatment. Until these questions can be fully addressed, it’s important to 
continue to study this topic and pursue the best possible treatment and care 
options for those suffering from MS.
Discussion Results 
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Safety and efficacy of mesenchymal stem cell (MSC) therapy in symptom management 
of multiple sclerosis as compared to the currently approved medications
The primary objective of the majority of the chosen studies was to assess the 
safety of MSC in the treatment of MS. Very few adverse effects were 
demonstrated in any of the studies, all of which resolved without need for 
intervention or treatment cessation. This is a promising aspect of the research, 
as it allows this research to move forward confidently. The most important next 
step in this field is to continue to expand the number of participants to gain 
more significant results.
While the studies failed to show significant outcomes and improvements in all 
the analyzed data, some significant results were seen and prove very 
promising. Many participants reported feeling better than they had prior to the 
study while being treated with MSCs. It remains to be seen if this is the effect 
of bias, but further studies which blind participants can perhaps eliminate that 
possibility. If results were to remain significant, it would be a great leap 
forward in this area of study.
Conclusion
1. Llufriu, S, et al.
1. Randomized double blind control trial with 9 
subjects
2. Dahbour, S, et al.
1. Open label prospective trial with 15 subjects 
3. Harris, VK, et al.
1. Open label single arm clinical trial with 20 subjects
4. Riordan, NH, et. Al.
1. Open label single arm clinical trial with 20 subjects
5. Cohen, JA, et al.
1. Open label pre/post comparison study with 24 
subjects
6. Jin-Feng Li, et al.
1. Randomized two arm control trial with 23 subjects 
7. Fernández, O, et al.
1. Placebo controlled triple blind study with 34 
subjects
All of the selected studies shared a primary objective of assesing
safety, many also assesing the efficacy of treatment as a secondary 
objective. All trials were successfully completed. Though some 
minor adverse events were experienced, the MSC treatment did 
not lead to any major life threatening events. The majority of the 
studies demonstrated significantly improved lesion volume on MRI, 
as well as significantly improved EDSS scores. 
Study EDSS Score MRI Lesion 
Volume
T25-FW 9HP
Llufriu, S, et 
al.
NS S N/A N/A
Dahbour, S, et 
al.
NS S NS S
Harris, VK, et 
al.
NS S S S
Riordan, NH, 
et. al.
S NS S S
Cohen, JA, et 
al.
NS S N/A N/A
Jin-Feng Li, et 
al.
S N/A N/A N/A
Fernández, O, 
et al.
NS NS N/A N/A
Key
EDSS-Expanded Disability Status Scale; T25-FW-Timed 25-Foot Walk; 9HP-9 Hole Peg; S-
significant; NS-not significant
C. Comparison of results
Image 1: Types of Multiple Sclerosis (MS). News-Medical
Imagine 2: What is a Stem Cell?. Your Genome
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